Qiu JiangPing, Wu Jiang, Zhou Nan, Lai Cong, Huang Xin, Liu Cheng, Yuan XiaoQing, Xu Kewei
Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, China.
Research Center, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, 510370, China.
Cancer Cell Int. 2025 Jul 1;25(1):240. doi: 10.1186/s12935-025-03886-9.
Prostate cancer(PCa) ranks among the most frequently diagnosed malignancies in men. The progression and heterogeneity of tumors pose significant challenges to clinical prognosis and treatment strategies. Recently, extrachromosomal DNA(ecDNA) has emerged as a critical player in cancer biology, influencing tumor progression, metastasis, and resistance to therapy. Oncogenes and regulatory sequences carried on ecDNA(ecDNA genes) can significantly alter the biological characteristics of tumors and their clinical outcomes.
In this study, we obtained ecDNA genes specifically expressed in PCa from the ECGA database. To construct a prognostic risk model for Biochemical Recurrence-Free Survival (BRFS), the two most common types of ecDNA genes which are protein-coding genes and long non-coding RNAs, were analyzed using Cox regression and LASSO regression techniques. Through KEGG/GO pathway enrichment analysis, we identified relevant pathways and analyzed the immune cell infiltration status. Functional assays, such as colony formation, CCK-8, migration, and invasion assays, were employed to assess the cellular functions of a key lncRNA AC016394.2.
Our analysis identified six key ecDNA lncRNAs(ec-lncRNAs), including the ec-lncRNA AC016394.2, with significant prognostic value in PCa. By employing our risk scoring model, patients were classified into high-risk and low-risk groups, revealing significant differences in their BRFS outcomes. The model demonstrated strong predictive accuracy and clinical relevance. The 1/3/5-year AUC of the model is close to 0.8, which is higher than most common clinical indicators such as Gleason score and TM staging. KEGG and GO pathway enrichment analyses revealed that the high-risk group was predominantly enriched in immune-related pathways. Additionally, immune cell infiltration analysis demonstrated notable differences in the distribution of specific immune cell populations between the high-risk and low-risk groups. Knockdown of AC016394.2 inhibited PCa cell proliferation, migration, and invasion.
This study presents a novel ecDNA gene-based prognostic risk model for PCa, highlighting the functional importance of ec-lncRNA AC016394.2. These findings offer valuable insights into the biological role of ec-lncRNAs, highlighting their potential as targets for precision oncology and therapeutic intervention.
前列腺癌(PCa)是男性中最常被诊断出的恶性肿瘤之一。肿瘤的进展和异质性对临床预后和治疗策略构成了重大挑战。最近,染色体外DNA(ecDNA)已成为癌症生物学中的关键因素,影响肿瘤进展、转移及对治疗的抗性。ecDNA携带的癌基因和调控序列(ecDNA基因)可显著改变肿瘤的生物学特性及其临床结局。
在本研究中,我们从ECGA数据库获取了在PCa中特异性表达的ecDNA基因。为构建生化无复发生存(BRFS)的预后风险模型,使用Cox回归和LASSO回归技术分析了两种最常见的ecDNA基因类型,即蛋白质编码基因和长链非编码RNA。通过KEGG/GO通路富集分析,我们确定了相关通路并分析了免疫细胞浸润状态。采用集落形成、CCK-8、迁移和侵袭实验等功能实验评估关键长链非编码RNA AC016394.2的细胞功能。
我们的分析确定了六个关键的ecDNA长链非编码RNA(ec-lncRNA),包括ec-lncRNA AC016394.2,其在PCa中具有显著的预后价值。通过使用我们的风险评分模型,患者被分为高风险和低风险组,显示出他们在BRFS结局上有显著差异。该模型显示出强大的预测准确性和临床相关性。该模型的1/3/5年AUC接近0.8,高于大多数常见临床指标,如Gleason评分和TM分期。KEGG和GO通路富集分析表明,高风险组主要富集在免疫相关通路。此外,免疫细胞浸润分析显示高风险组和低风险组之间特定免疫细胞群体的分布存在显著差异。敲低AC016394.2可抑制PCa细胞的增殖、迁移和侵袭。
本研究提出了一种基于ecDNA基因的新型PCa预后风险模型,突出了ec-lncRNA AC016394.2的功能重要性。这些发现为ec-lncRNA的生物学作用提供了有价值的见解,突出了它们作为精准肿瘤学和治疗干预靶点的潜力。